End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6.33 CNY | -0.31% | +3.60% | -8.26% |
Apr. 16 | Yabao Pharma Gets Nod to Register Asthma Drug Montelukast Sodium Granules | MT |
Apr. 02 | Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023. | CI |
Sales 2021 | 2.76B 382M | Sales 2022 | 2.72B 375M | Capitalization | 4.53B 625M |
---|---|---|---|---|---|
Net income 2021 | 187M 25.83M | Net income 2022 | 105M 14.51M | EV / Sales 2021 | 2.55 x |
Net Debt 2021 | 61.69M 8.52M | Net cash position 2022 | 227M 31.34M | EV / Sales 2022 | 1.58 x |
P/E ratio 2021 |
37.4
x | P/E ratio 2022 |
43.3
x | Employees | 4,367 |
Yield 2021 |
0.88% | Yield 2022 |
0.85% | Free-Float | 90.62% |
1 day | -0.31% | ||
1 week | +3.60% | ||
Current month | +1.93% | ||
1 month | +3.09% | ||
3 months | +0.80% | ||
6 months | -17.25% | ||
Current year | -8.26% |
Managers | Title | Age | Since |
---|---|---|---|
Wei Ren
CEO | Chief Executive Officer | 40 | 19-04-22 |
Zhe Feng Zuo
DFI | Director of Finance/CFO | 52 | - |
Wu Xian Ren
CHM | Chairman | 64 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Wu Xian Ren
CHM | Chairman | 64 | - |
Zhen Jiang Xu
CHM | Chairman | 51 | 14-05-14 |
Peng Bo Ren
BRD | Director/Board Member | 51 | 07-03-10 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +2.22% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 6.33 | -0.31% | 12,043,810 |
24-04-24 | 6.35 | +2.09% | 18,197,120 |
24-04-23 | 6.22 | +1.14% | 11,747,700 |
24-04-22 | 6.15 | +0.49% | 10,258,900 |
24-04-19 | 6.12 | +0.16% | 9,347,600 |
End-of-day quote Shanghai S.E., April 24, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
-8.26% | 619M | |
+18.59% | 22.25B | |
+13.49% | 14.39B | |
+12.83% | 13.55B | |
+38.02% | 11.27B | |
-9.80% | 6.95B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+6.35% | 5.01B | |
-5.36% | 4.51B |
- Stock Market
- Equities
- 600351 Stock